- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04146012
BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial (BEACH)
Bovine Early Access, Compatibility and Hemostasis Post-Market Trial to Evaluate the Safety and Effectiveness of Early Access in Patients Who Require an Arteriovenous Conduit for Hemodialysis Using the Artegraft® Collagen Vascular Graft™
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic kidney disease (CKD) is a major health problem that affects approximately 26 million Americans. Many of those suffering CKD will progress to develop end stage renal disease (ESRD) and require lifelong hemodialysis (HD) to filter wastes from their blood. There are nearly 2.5 million patients who receive HD worldwide, and this population is growing at a rate of 8% per year. This projects that the worldwide HD population to reach approximately 3.4 million by the year 2020. There are over 600,000 patients on HD in the US and an estimated 100,000 new cases are reported annually. The interventions required to maintain a person on HD carry a significant financial burden, with costs estimated to be as high as $30 billion annually. Given the increasing epidemic of obesity, diabetes, and heart disease, the burden of ESRD will continue to grow, making new interventions that can improve the social, physical, and financial realities of treating ESRD essential.
A critical factor in the survival of renal dialysis patients is the surgical creation of vascular access. Despite the fistula-first initiative, many patients will start hemodialysis using a central venous catheter (CVC). This increases the risks of associated bloodstream infections, central venous stenosis, and poorer outcomes from subsequent vascular cannulations.
Arteriovenous grafts have advantages compared with central venous catheters for dialysis and guidelines suggest their use as second choice after arteriovenous fistulas. The suggested advantages of grafts over fistulas is the ability to cannulate or access the graft earlier, traditionally 2 weeks for AVG rather than 6 weeks for AVF, and the lower rates of primary failure.
Standard practice with expanded polytetrafluoroethylene (ePTFE) grafts has been to avoid cannulation for 2 weeks following placement, but new generation grafts have been marketed for their early cannulation properties allowing use as an alternative to central venous catheters for prompt access.
The proposed BEACH Trial is a multi-center, prospective clinical trial to evaluate early access of an existing, FDA-approved bovine carotid vascular graft, approved as a general peripheral vascular graft and for hemodialysis. The BEACH Trial is seeking to demonstrate that early access, defined as within 72 hours post implantation, of the Artegraft device results in acceptable clinical outcomes including ability to support dialysis needs thereby obviating the requirement for interim catheter placement or facilitating the removal of an existing catheter with acceptable composite major adverse clinical events (MACE) rate up to 26 weeks (6 months) post implant.
Few vascular products approved in the 1970s have a broad level of acceptance in today's competitive market. Review of the original NDA application for Artegraft as well as the scientific literature revealed no clinical rationale for a waiting period of 14 days (for most access grafts) and 10 days (for Artegraft) before cannulation. The current literature does not seem to support the current guidelines as there is no evidence to suggest that a delay in cannulation of PTFE grafts will improve graft survival and patency.Note also that Artegraft cannot identify any scientific justification in the original NDA for the warning that was placed in the IFU to support the 10-day waiting period before cannulation.
Further, if it is assumed that dialysis is conducted 3 times per week, by allowing cannulation to the Artegraft device in the 72-hour period, only 6 to 10 additional needle punctures are added during the first 10-day period depending on whether cannulation is initiated within 72 hours, respectively. Artegraft believes that this limited number of additional early needle punctures will not significantly affect the safety or efficacy of the graft or the cannulation procedure.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92093
- University of California
-
-
New York
-
Albany, New York, United States, 12209
- Capital District Renal Physicians
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Dialysis Access Institute
-
Spartanburg, South Carolina, United States, 29303
- Spartanburg Regional Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75218
- City Hospital at White Rock
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients are eligible to be included in the study only if they meet the following criteria:
- Male or Female, 18 years or older
- Diagnosis of End Stage Renal Disease (ESRD) and require vascular access for hemodialysis
- Native [autogenous tissue] AV fistula creation or access is not indicated or non-viable [disadvantaged veins]
- Requiring repair of an existing fistula or conduit, but only if using Artegraft as an interposition placement and the Artegraft is cannulated [not the fistula]. Artegraft must be place in a fresh subcutaneous tunnel. Thigh loop grafts will not be used.
- Able to accommodate vascular graft placement in the upper extremity (i.e., forearm, or upper arm)
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
- Able and willing to comply with the study protocol
- Agrees to initiate and maintain hemodialysis treatments
- Life expectancy is > 1 year based on physician assessment
Exclusion Criteria:
Patients are excluded from the trial if any of the following criteria apply:
- High grade central venous stenosis/occlusion
- Breast-feeding, pregnant or planning pregnancy within next 12 months.
- Non-resolved infected existing grafts
- Documented sepsis/bacteremia by blood culture within 4 weeks of implantation.
- History of non-controlled immunodeficiency syndrome, including AIDS/HIV; Active clinically significant immune-mediated disease, not controlled by low-dose maintenance immunosuppression. The diagnosis of HIV alone, provided adequately treated, is not a contraindication for enrolment.
- Severe liver dysfunction and/or coagulation or bleeding disorders.
- Elevated platelet count > 1 million cells/mm3
- History of heparin-induced thrombocytopenia syndrome (HIT)
- Documented hypercoagulable state
- Currently participating in another investigational drug or device study which may clinically interfere with any endpoints of this trial
- Known hypersensitivity or contraindication to device materials or procedural medications that cannot be adequately managed medically
- History or evidence of severe cardiac disease (NYHA Functional Class III or IV), , myocardial infarction within 6 months of enrollment, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina, uncontrolled CHF
- History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e. arterial inflow insufficient to support hemodialysis)
- History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin
- Bleeding diathesis, other than that associated with ESRD
- Scheduled renal transplant within 6 months
- Patients who require chronic anticoagulation except for antiplatelet therapy. Patients currently receiving or who have received within the last month direct thrombin inhibitors, factor Xa inhibitors, or vitamin K antagonists should not be included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Early Access
Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed in less than 72 hours after implantation.
|
The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
|
Active Comparator: Normal Access
Artegraft® Collagen Vascular Graft™ (Artegraft) will be accessed after 10 days as per current IFU.
|
The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants That Were Successfully Cannulated.
Time Frame: less than 72 hours
|
Early access success, defined by three cannulations, the first one started within 72 hours after implantation, all with minimum dialysis flow rates of 250 ml/min pump flow rate, with a minimum 17-gauge needle.
|
less than 72 hours
|
Patients That Experienced Major Adverse Events
Time Frame: Less than 6 month
|
A composite of major adverse clinical events (MACE) including perigraft infection, hemorrhage / hematoma, thrombosis, and pseudoaneurysm within 30 days after first cannulation [Day 0] in the early-access and late-access groups.
|
Less than 6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grafts That Were Patent After 30 Days
Time Frame: Less than 6 months
|
Patency (Primary, Assisted Primary, and Secondary) at 30 days after first successful cannulation [Day 0], and at 12 and 6 months after implantation in the early-access group and at 30 days post-Day 0 in the late-access group.
The late access group will also be assessed for patency at 6 months through a telephone interview or office visit to provide a more robust data set.
|
Less than 6 months
|
Patients That Experience Major Adverse Events
Time Frame: Less than 6 months
|
All adverse events will be collected in the early-access group [to 6 months] and the late-access group [to 30 days post Day 0] and summarized by unique event, seriousness, and relationship to device or procedure.
|
Less than 6 months
|
Removal of Catheter After Implantation (For Information Only)
Time Frame: Less than 6 months
|
The number of days from graft implant or fistula revision to catheter removal shall be recorded.
|
Less than 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mahmoud Malas, MD, University of California, San Diego
Publications and helpful links
General Publications
- Fresenius Medical Care : Fresenious Medical Care Annual Report 2011 - Dialysis Market, Bad Homburg, Germany, Freesenious Medical Care, 2011
- US Renal Data System: 2012 Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
- US Renal Data System: 2014 Annual Data Report : Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
- Manns B, Tonelli M, Yilmaz S, Lee H, Laupland K, Klarenbach S, Radkevich V, Murphy B. Establishment and maintenance of vascular access in incident hemodialysis patients: a prospective cost analysis. J Am Soc Nephrol. 2005 Jan;16(1):201-9. doi: 10.1681/ASN.2004050355. Epub 2004 Nov 24.
- Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002 Aug;62(2):620-6. doi: 10.1046/j.1523-1755.2002.00460.x.
- Al Shakarchi J, Inston N. Timing of cannulation of arteriovenous grafts: are we too cautious? Clin Kidney J. 2015 Jun;8(3):290-2. doi: 10.1093/ckj/sfu146. Epub 2015 Jan 20.
- US Renal Data System, Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States, Bethesda MD, National Institutes of Health, National Institute of Diabetes and Kidney Diseases, 2009
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARTCT.BEACH.001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Insufficiency,Chronic
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
University of PennsylvaniaTeleflex; Arrow InternationalCompletedRenal Failure Chronic Requiring Hemodialysis | Chronic Renal InsufficiencyUnited States
-
Hospices Civils de LyonCompletedChronic Renal Insufficiency | Cardiac TransplantationFrance
-
CHU de ReimsUnknownChronic Renal InsufficiencyFrance
-
Southern Medical University, ChinaTerminatedChronic Kidney Failure
-
Centre Hospitalier Universitaire de NiceTerminatedAged | Chronic Renal Insufficiency | Chronic Kidney FailureFrance
-
Azienda Sanitaria ASL Avellino 2UnknownChronic Renal InsufficiencyItaly
-
Assistance Publique Hopitaux De MarseilleCompletedChronic Renal InsufficiencyFrance
Clinical Trials on Artegraft® Collagen Vascular Graft™ (Artegraft)
-
W.L.Gore & AssociatesRecruitingEnd-Stage Renal Disease | AAA - Abdominal Aortic Aneurysm | PAD - Peripheral Arterial DiseaseSpain, Italy, France
-
W.L.Gore & AssociatesCompletedEnd Stage Renal Disease
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedEvaluation of Two Types of Matrix (Mucograft® and Mucoderm®) Associated With Coronally Advanced FlapGingival RecessionBrazil
-
W.L.Gore & AssociatesRecruitingChronic Kidney Diseases | End Stage Renal Disease on DialysisUnited Kingdom, Germany, Italy
-
Angiotech PharmaceuticalsTerminatedHyperplasia | End Stage Renal Failure on DialysisUnited States
-
Datum Dental LTDCompleted
-
Hams Hamed AbdelrahmanAlexandria UniversityCompleted
-
Cook Group IncorporatedCompleted
-
Göteborg UniversityOsteology FoundationActive, not recruiting
-
Cook Research IncorporatedCompletedThoracic Injuries | Thoracic Aorta | Blunt InjuriesUnited States